![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Spear Requests FDA Uphold Bioequivalence Requirements for Efudex
Spear Requests FDA Uphold Bioequivalence Requirements for Efudex
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
March 14, 2018
Spear Pharma sent a citizen’s petition to the FDA, requesting that the agency maintain bioequivalence requirements for abbreviated new drug applications that cite Spear’s product Efudex (fluorouracil) as a reference listed drug and seek regulatory approval of a topical generic drug product.
The firm stated that 5-flourouracil is a cytotoxic drug that can have severe side effects with overexposure, arguing that a clinical trial is the only safe way to test the bioequivalence of a generic Efudex product and assure its side effects and severity are no worse than those of the reference drug.
It also said its product should not be a priority for alternative bioequivalence pathways because three generic versions of Efudex are already on the market.
Upcoming Events
-
21Oct